Intervista a Maurizio Gallieni

Bischoff-Ferrari H.A. , Giovannucci E. , Willett W.C. , Dietrich T. , Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006; 84: 18–28.

Gallieni M. , Kamimura S. , Ahmed A. , Bravo E. , Delmez J. , Slatopolsky E. , Dusso A. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol. 1995; 268: F746–53.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113): S1–130

Wanner C. , Krane V. , März W. , Olschewski M. , Mann J.F. , Ruf G. , Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med. 2005; 353: 238–48.

Fellström B.C. , Jardine A.G. , Schmieder R.E. . Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. New Engl J Med. 2009; 360: 1395–407.

Unger E.F. , Thompson A.M. , Blank M.J. , Temple R. Erythropoiesis-stimulating agents–time for a reevaluation. N Engl J Med. 2010; 362: 189–92.

Suki W.N. , Zabaneh R. , Cangiano J.L. . Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007; 72: 1130–7.

Chertow G.M. , Burke S.K. , Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245–52.

Block G.A. , Raggi P. , Bellasi A. , Kooienga L. , Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438–41.

Brancaccio D. , Gallieni M. , Pasho S. . Pathogenesis and treatment of vascular calcification in CKD. G Ital Nefrol. 2009; 26(Suppl 45): S20–7.

Memon F. , El-Abbadi M. , Nakatani T. , Taguchi T. , Lanske B. , Razzaque M.S. Does FGF23-Klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? FGF23, Klotho, and calcification. Kidney Int 2008; 74: 566–570.

Agarwal R. , Vitamin D. , proteinuria, diabetic nephropathy, and progression of CKD. Clin J Am Soc Nephrol 2009; 4: 1523–1528.

Lambers Heerspink H.J. , Agarwal R. . The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. Am J Nephrol. 2009; 30: 280–6.